BACKGROUND: Fetal cells (microchimerism) are acquired by women during pregnancy. Fetal microchimerism persists decades later and includes cells with pluripotent capacity. Persistent microchimerism has the capacity for both beneficial and detrimental maternal health consequences. Both miscarriage and termination of pregnancy can result in fetal microchimerism. We sought to determine whether cellular fetal microchimerism is acquired during management of pregnancy loss and further explored factors that could influence fetal cell transfer, including viability of fetal tissue, surgical versus medical management and gestational age. METHODS: Pregnant women (n= 150 samples from 75 women) with singleton pregnancies undergoing a TOP (n= 63) or treatment for embryonic or fetal demise (miscarriage, n= 12) were enrolled. Mononuclear cells were isolated from blood samples drawn before, and 30 min after, treatment. Fetal cellular microchimerism concentrations were determined using quantitative PCR for a Y chromosome-specific sequence, expressed as genome equivalents of fetal DNA per 100 000 maternal cell equivalents (gEq/10(5)). Detection rate ratios were determined according to clinical characteristics. RESULTS: Cellular fetal microchimerism was found more often in post- compared with pretreatment samples, 24 versus 5% (P= 0.004) and at higher concentrations, 0-36 versus 0-0.7 gEq/10(5) (P< 0.001). Likelihood of microchimerism was higher in surgical than medical management, detection rate ratio 24.7 (P= 0.02). The detection rate ratio for TOP versus miscarriage was 16.7 for known male fetuses (P= 0.02). Microchimerism did not vary with gestational age. CONCLUSIONS: Significant fetal cell transfer occurs during miscarriage and TOP. Exploratory analyses support relationships between obstetric clinical factors and acquisition of fetal cellular microchimerism; however, our limited sample size precludes definitive analysis of these relationships, and confirmation is needed. In addition, the long-term persistence and potential consequences of fetal microchimerism on maternal health merit further investigation.
BACKGROUND: Fetal cells (microchimerism) are acquired by women during pregnancy. Fetal microchimerism persists decades later and includes cells with pluripotent capacity. Persistent microchimerism has the capacity for both beneficial and detrimental maternal health consequences. Both miscarriage and termination of pregnancy can result in fetal microchimerism. We sought to determine whether cellular fetal microchimerism is acquired during management of pregnancy loss and further explored factors that could influence fetal cell transfer, including viability of fetal tissue, surgical versus medical management and gestational age. METHODS: Pregnant women (n= 150 samples from 75 women) with singleton pregnancies undergoing a TOP (n= 63) or treatment for embryonic or fetal demise (miscarriage, n= 12) were enrolled. Mononuclear cells were isolated from blood samples drawn before, and 30 min after, treatment. Fetal cellular microchimerism concentrations were determined using quantitative PCR for a Y chromosome-specific sequence, expressed as genome equivalents of fetal DNA per 100 000 maternal cell equivalents (gEq/10(5)). Detection rate ratios were determined according to clinical characteristics. RESULTS: Cellular fetal microchimerism was found more often in post- compared with pretreatment samples, 24 versus 5% (P= 0.004) and at higher concentrations, 0-36 versus 0-0.7 gEq/10(5) (P< 0.001). Likelihood of microchimerism was higher in surgical than medical management, detection rate ratio 24.7 (P= 0.02). The detection rate ratio for TOP versus miscarriage was 16.7 for known male fetuses (P= 0.02). Microchimerism did not vary with gestational age. CONCLUSIONS: Significant fetal cell transfer occurs during miscarriage and TOP. Exploratory analyses support relationships between obstetric clinical factors and acquisition of fetal cellular microchimerism; however, our limited sample size precludes definitive analysis of these relationships, and confirmation is needed. In addition, the long-term persistence and potential consequences of fetal microchimerism on maternal health merit further investigation.
Authors: D W Bianchi; A Farina; W Weber; L C Delli-Bovi; M Deriso; J M Williams; K W Klinger Journal: Am J Obstet Gynecol Date: 2001-03 Impact factor: 8.661
Authors: N Schupf; D Kapell; B Nightingale; J H Lee; J Mohlenhoff; S Bewley; R Ottman; R Mayeux Journal: Neurology Date: 2001-09-25 Impact factor: 9.910
Authors: Nathalie C Lambert; Y M Dennis Lo; Timothy D Erickson; Tracy S Tylee; Katherine A Guthrie; Daniel E Furst; J Lee Nelson Journal: Blood Date: 2002-10-15 Impact factor: 22.113
Authors: Tuangsit Wataganara; Angela Y Chen; Erik S LeShane; Lisa M Sullivan; Lynn Borgatta; Diana W Bianchi; Kirby L Johnson Journal: Fertil Steril Date: 2004-03 Impact factor: 7.329
Authors: Amelie Fassbender; Maria Debiec-Rychter; Rieta Van Bree; Joris Robert Vermeesch; Christel Meuleman; Carla Tomassetti; Karen Peeraer; Thomas D'Hooghe; Dan I Lebovic Journal: Reprod Sci Date: 2015-03-05 Impact factor: 3.060
Authors: Raj Shree; Stephen McCartney; Emma Cousin; Angel Chae; Hilary S Gammill; J L Nelson; Sami B Kanaan Journal: Reprod Sci Date: 2022-09-27 Impact factor: 2.924
Authors: R Shree; W E Harrington; S B Kanaan; A Forsyth; E Cousin; A Lopez; J L Nelson; H S Gammill Journal: BJOG Date: 2018-09-24 Impact factor: 6.531